Impaired hemodynamics of the patella in patients with patellofemoral pain: A case-control study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 38455453.
- Also identified by DOI 10.1002/jeo2.12009 and PMC identifier 10900186.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
According to the homeostasis model, patellofemoral pain (PFP) arises as a consequence of disturbed homeostasis of anterior structures of the knee due to vascular insufficiency. Near-infrared spectroscopy (NIRS) allows to measure changes of concentrations (µmol/cm<sup>2</sup>) of (de)-oxygenated hemoglobine (HHb and O<sub>2</sub>Hb). The aim was to study differences in patellar hemodynamics between patients and healthy controls. Hemodynamics of patients (<i>n</i> = 30 [female = 20, age = 21.5, BMI = 22.9]) and controls (<i>n</i> = 30 (female = 18, age = 21.4, BMI = 22.4]) were evaluated for two activities ('Prolonged Sitting' and 'Stair Descent'). Blinding for health status was implemented. During 'Prolonged Sitting', PFP patients exhibited smaller decreases in mean changes for HHb (PFP [<i>M</i> = -1.5 to -1.9], healthy controls [<i>M</i> = -2.0 to -2.3]) and O<sub>2</sub>Hb (PFP [<i>M</i> = -2.0 to -3.2], healthy controls [<i>M</i> = -3.4 to -4.1]). However, these differences were statistically non-significant (<i>p</i> = 0.14-0.82 and <i>p</i> = 0.056-0.18, respectively). Conversely, for 'Stair Descent', PFP patients showed statistically significant smaller decreases in mean changes for HHb (PFP [<i>M</i> = -1.9, SD = 1.8], healthy controls [<i>M</i> = -2.5, SD = 1.7], <i>p</i> = 0.043) and O<sub>2</sub>Hb (PFP [<i>M</i> = -3.2, SD = 3.2], healthy controls [<i>M</i> = -4.9, SD = 2.7], <i>p</i> = 0.004). The differences suggest potential impairment in patellar hemodynamics in PFP patients, providing support for the homeostasis model. Evidence-based treatment strategies targeting patellar hemodynamics should be further refined and subjected to evaluation in clinical trials. Level III.